Sourcing · Regulatory

Prescription requirements and telehealth models — a second dataset

Sourcing › Regulatory compounding EMA MHRA personal import FDA research use only

microgramsTL2Regular9 Apr 2026#1

On the subject in the title: Prescription requirements and telehealth models — a second dataset Working notes rather than a conclusion.

A logistics question, since the answers here are usually better than anywhere else I have looked.

Parcel despatched 13 days ago, tracking last updated 7 days ago at a customs facility, no further movement. Cold pack included at despatch.

Two questions. First, at what point is this genuinely a problem rather than an ordinary delay? Second, if it does arrive, what is the actual decision process for assessing it, as opposed to the two extremes people usually offer?

7 likes 4mo

o.lindgrenTL2Regular12 Apr 2026 · edited#2

Preclinical versus clinical: compounds with strong preclinical data can fail in clinical trials. Compounds with no human data are being used on theoretical grounds. The regulatory position reflects this asymmetry.

11 likes 4mo

a.pereiraTL2 Moderator14 Apr 2026#3

micrograms, post #1: On the subject in the title: Prescription requirements and telehealth models — a second dataset Working notes rather than a conclusion. A logistics question, since the answers here are usually better than anywhere else I have looked. Parcel despatched 13 days ago, tracking last updated 7 days ago at a customs facility, no further… Go to post

post #2 answers the question as asked. The question underneath it is different.

Why this category is maintained as documentation, not as recommendations: the goal is factual accuracy and sourcing, not endorsement of any specific regulatory position.

24 likes in reply to #1 3mo

forest_plotTL3Evidence synthesis15 Apr 2026#4

Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.

0 likes 3mo

h.bakkerTL2 Moderator17 Apr 2026#5

For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.

1 like 3mo

ppm_errorTL3Analytical chemist18 Apr 2026#6

I read post #4 twice before replying, because I had assumed the opposite.

Regulatory positions change: a compound's status today might differ from its status a year from now. Citing a regulatory position is worth doing only with a date attached.

7 likes 3mo

d.eriksenTL2 Moderator20 Apr 2026#7

o.lindgren, post #2: Preclinical versus clinical: compounds with strong preclinical data can fail in clinical trials. Compounds with no human data are being used on theoretical grounds. The regulatory position reflects this asymmetry. Go to post

Labelling and intended use: a compound sold as "research-use-only" does not change its pharmacology if ingested. It changes the legal status of the sale. The labelling tells you the intended use, not the actual use people make of it.

17 likes in reply to #2 3mo

m.strand_rphTL3Pharmacist21 Apr 2026#8

forest_plot, post #4: Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive. Go to post

Off-label use and medical practice: clinicians can prescribe approved medications off-label under some circumstances. That is different from research-use-only compounds, which are not approved for any human use.

0 likes in reply to #4 3mo

s.kimaniTL2 Moderator22 Apr 2026#9

Picking up post #6: that is the part I would want checked first.

Research-use-only status is a legal classification, not a safety classification. It means the compound is sold for laboratory use and not for human consumption. The label does not establish whether the molecule is safe, efficacious, or toxic.

11 likes 3mo

j.mwangiTL4 Moderator23 Apr 2026#10

Staff post. Actions described here are recorded in the public moderation log and may be challenged in Meta.

Coming back to post #8, because the follow-up matters more than the original answer.

23 likes 3mo

glossary_deskTL3Regular25 Apr 2026#11

Compounding and pharmacy rules: some jurisdictions allow a pharmacy to compound a drug that is not on the market under specific conditions. The conditions are strict and vary by jurisdiction. Generalising from one country's rules to another's is unreliable.

2 likes 3mo

a.vestergaardTL2 Moderator26 Apr 2026#12

Import restrictions vary by compound and by jurisdiction: what is a controlled substance in one place is legal to purchase in another. What you can import for personal use depends on your country's rules, not on where it is sold.

0 likes 3mo

glossary_checkTL2Member27 Apr 2026#13

d.eriksen, post #7: Labelling and intended use: a compound sold as "research-use-only" does not change its pharmacology if ingested. It changes the legal status of the sale. The labelling tells you the intended use, not the actual use people make of it. Go to post

Two things before anyone answers the substance.

First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.

20 likes in reply to #7 3mo

l.krastevTL228 Apr 2026#14

Collapsed as off-topic by two members at trust level 3 or above

Picking up post #11: that is the part I would want checked first.

Primary documents matter: regulatory positions are published in official documents. Reading the regulatory agency's website directly is more reliable than reading a forum summary of it.

aliquot_lineTL3Regular29 Apr 2026#15

Worth separating two things that post #11 runs together.

5 likes 3mo

e.nilsenTL2 Moderator30 Apr 2026 · edited#16

a.vestergaard, post #12: Import restrictions vary by compound and by jurisdiction: what is a controlled substance in one place is legal to purchase in another. What you can import for personal use depends on your country's rules, not on where it is sold. Go to post

I disagree with the reply above, and I think the disagreement is substantive rather than terminological.

The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.

0 likes in reply to #12 3mo

GEldridgeTL3Regular2 May 2026#17

28 likes in reply to #7 3mo

a.krastevTL2 Moderator3 May 2026#18

13 likes 3mo

resistance_firstTL2Regular4 May 2026 · edited#19

On post #15 — agreed on the reasoning, with one qualification.

Regulatory positions change: a compound's status today might differ from its status a year from now. Citing a regulatory position is worth doing only with a date attached.

8 likes 3mo

c.haddadTL2 Moderator5 May 2026#20

glossary_check, post #13: Two things before anyone answers the substance. First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound. Go to post

post #19 answers the question as asked. The question underneath it is different.

Primary documents matter: regulatory positions are published in official documents. Reading the regulatory agency's website directly is more reliable than reading a forum summary of it.

2 likes in reply to #13 3mo

s.demirTL2 Moderator6 May 2026 · edited#21

post #20 is right about the mechanism and I think understates the practical bit.

Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up.

3 likes 3mo

o.pasqualeTL1Member7 May 2026#22

10 likes 3mo

i.dumitruTL2 Moderator8 May 2026#23

s.kimani, post #9: Picking up post #6: that is the part I would want checked first. Research-use-only status is a legal classification, not a safety classification. It means the compound is sold for laboratory use and not for human consumption. The label does not establish whether the molecule is safe, efficacious, or toxic. Go to post

Why this category is maintained as documentation, not as recommendations: the goal is factual accuracy and sourcing, not endorsement of any specific regulatory position.

23 likes in reply to #9 3mo

endpoint_lineTL3Regular9 May 2026#24

aliquot_line, post #15: Worth separating two things that post #11 runs together. Research-use-only status is a legal classification, not a safety classification. It means the compound is sold for laboratory use and not for human consumption. The label does not establish whether the molecule is safe, efficacious, or toxic. Go to post

I read post #22 twice before replying, because I had assumed the opposite.

0 likes in reply to #15 3mo

s.ivaturiTL2 Moderator10 May 2026#25

1 like 3mo

citation_peakTL3Regular11 May 2026#26

Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.

The correction was fair and I had been repeating something I had not checked carefully enough.

6 likes 3mo

ma.nascimentoTL2 Moderator12 May 2026#27

l.krastev, post #14: Picking up post #11: that is the part I would want checked first. Primary documents matter: regulatory positions are published in official documents. Reading the regulatory agency's website directly is more reliable than reading a forum summary of it. Go to post

Picking up post #24: that is the part I would want checked first.

Approval versus licensing: a compound can be approved for a specific indication in one country and not approved at all in another. Tracking jurisdictional approval is tedious but necessary.

16 likes in reply to #14 3mo

l.parkinsonTL2Member13 May 2026#28

Coming back to post #26, because the follow-up matters more than the original answer.

32 likes 3mo

d.ndiayeTL2 Moderator14 May 2026#29

s.demir, post #21: post #20 is right about the mechanism and I think understates the practical bit. Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up. Go to post

0 likes in reply to #21 2mo

WickramasingheTL2Member15 May 2026#30

Worth separating two things that post #26 runs together.

Approval versus licensing: a compound can be approved for a specific indication in one country and not approved at all in another. Tracking jurisdictional approval is tedious but necessary.

3 likes 2mo

Sponsored PeptideMeter — peptide analytics and supplier verificationPurity analysis and structured supplier verification, published as dated records rather than scores. Referenced throughout our sourcing documentation.View analytics →